top of page

GynOncoGroup_Logo Final_NoTag.png

Search

Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer (RAINFOL-02)

GynOnco Group Team
Aug 16
1 min read

ree

STUDY ID: NCT06619236

STATUS: Enrolling

CONDITION: Ovarian Cancer

SPONSOR: Genmab

FOR MORE INFORMATION VISIT: https://clinicaltrials.gov/study/NCT06619236

Recent Posts

A Phase III Trial of One vs. Two Years of Maintenance Olaparib, with or Without Bevacizumab, in Patients with BRCA1/2 Mutated or Homologous Recombination Deficient (HRD+) Ovarian Cancer Following Resp

A Phase III Trial of One vs. Two Years of Maintenance Olaparib, with or Without Bevacizumab, in Patients with BRCA1/2 Mutated or Homologous Recombination Deficient (HRD+) Ovarian Cancer Following Resp

Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (NRG-GY019)

Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (NRG-GY019)

bottom of page